News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stratagene Revenue Grows 16% In Second Quarter; Strong Growth For QPCR And Mutagenesis Product Lines; Gain On Asset Sale Partially Offsets Hycor Merger Costs



10/19/2005 5:11:09 PM

Stratagene Corp. (Nasdaq:STGN), a developer, manufacturer and marketer of specialized life science research and immunodiagnostic products, today released financial results for the second quarter ended June 30, 2004. Stratagene was a privately held company until June 2, 2004, when it merged with Hycor Biomedical Inc. (formerly Nasdaq:HYBD) with Hycor surviving as a wholly owned subsidiary of Stratagene. Stratagene's second quarter and first half 2004 results include the historical results of Stratagene combined with the results of Hycor from the effective date of the merger through June 30, 2004.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES